INFO - Clinical research trial for lupus nephritis

[Guest guest]

The Lupus Foundation of America wishes to inform you about a clinical

research study to evaluate an alternative, investigational medication that

may help to treat lupus nephritis.

Although there are treatments available for lupus nephritis that include the

use of immunosuppressive and cytotoxic drugs (in conjunction with

corticosteroids), new options are being explored.

If you or someone you know has lupus nephritis, you may want to know more.

The purpose of this study is to provide further information on the effect of

mycophenolate mofetil (MMF), sold under the brand name CellCept, in the

initial treatment of lupus nephritis (induction phase) and to assess how

well it maintains this effect over longer periods (maintenance phase), when

compared to the current standard treatments. The safety of MMF in the

long-term treatment of lupus nephritis will also be assessed.

To be eligible for participation in this study, a person must:

Be 12 to 75 years of age,

Have a diagnosis of lupus, and

Have received a kidney biopsy in the last 6 months confirming a medical

diagnosis of lupus nephritis.

There are two separate treatment phases in this study. The first phase will

last for 6 months and the second will last for a further 3 years. The

treatment in the first phase will consist of corticosteroids plus either the

investigational medication or a comparator medication. The treatment in the

second phase will consist of corticosteroids plus either the investigational

medication or a different comparator medication. Participants will not know

which treatment they have been randomized to.

Qualified participants will receive a study-related medical evaluation,

including laboratory work, and study medication at no cost. Reimbursement

for travel will also be provided.

This study is being conducted at sites located in the following U.S. states:

AL, CA, CO, FL, GA, IL, MA, MD, MO, NC,NY, OH, OK, PA, SC, TX.

To find out more about this research study, the qualifications for

participation, and to locate a study site near you, call 011-800-111-25252.

(See below if you live outside the U.S.). This is a toll-free call. If you

prefer to communicate via email, send your message to ALMS@....

For information on the web about this study, go to:

http://www.almstudy.com/pp_patients_prospects.htm

or

http://www.clinicaltrials.gov/ct/show/NCT00121082?order=4

Thank you for your interest in this study.

*This toll free number is available in Australia, Canada, China, Eire,

France, Germany, Italy, Singapore, Spain, UK and USA. The '+' in front of a

toll free phone number indicates the need to dial a local international

access number. These are: Australia 0011, Canada 011, China 00, Eire 00,

France 00, Germany 00, Italy 00, Singapore 001, Spain 00, USA 011 e.g. from

the USA call 011 800 111 25252.

A PDF of the study poster: http://www.lupus.org/news/almsStaffposter.pdf

The study brochure:

http://www.clinicaltrials.gov/ct/show/NCT00121082?order=4

Message sent by:

Lupus Foundation of America, Inc.

2000 L Street, N.W., Suite 710

Washington, DC 20036

202-349-1155

info@... - www.lupus.org

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org